According to a research report "Plasma Fractionation Market in terms of revenue was estimated to be worth $26.5 billion in 2022 and is poised to reach $36.3 billion by 2027, growing at a CAGR of 6.5% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The market size is updated for the base year of 2021 and forecasted from 2022 to 2027 by studying the impact of the overall plasma fractionation industry. The new version of the report includes ranges and scenarios, value chain analysis, ecosystem analysis, technology analysis, patent analysis, trends and disruptions impacting customers, Porter’s five forces analysis, and a regulatory landscape. In the earlier version of the report, 20 companies were profiled. In the updated version, a total of 25 companies have been profiled. Market growth is driven mainly by factors such as the growing use of immunoglobulins in various therapeutic areas, the rapidly growing geriatric population, and the rising prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD). However, high costs, limited reimbursements, and the market disruption caused by recombinant alternatives are expected to restrain the growth of this market to a certain extent during the forecast period.

Download Report Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93798284

The growing use of immunoglobulins in various off-label indication and growing genetic research for characterizing and diagnosing immunodeficiency resulting in increased application of plasma fractionation products, growing geriatric population such as the population of people above 60 age expected to reach 2.1 billion by 2050, increased use of protease inhibitors such as alpha-1-antitrypsin for the treatment of lung diseases, and increased incidence of communicable diseases are the major factors driving the growth of this market.

Key Market Player:

The plasma fractionation market is an oligopolistic market. The prominent players operating in this market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India).

Driver: Growing use of immunoglobulins for various therapeutic area

The increasing use of immunoglobulins for various therapeutic areas, such as autoimmune diseases, immune deficiencies, and infectious diseases, is driving the growth of the plasma fractionation market. Immunoglobulins are proteins produced by the immune system to fight against infections, allergies, and other diseases. Plasma fractionation processes are used to extract immunoglobulins from the plasma of healthy donors. These immunoglobulins are then used to treat various diseases, such as primary immunodeficiencies, autoimmune diseases, and infectious diseases. In addition, the increasing demand for immunoglobulins in the research sector is also driving the growth of the plasma fractionation market.

Restraint: Use of recombinant alternatives for certain plasma products

The use of recombinant alternatives for certain plasma products such as factor VIII, IX and von Willebrand factor is a key restraint for the growth of the plasma fractionation market. The advent of recombinant alternative products has enabled more efficient and cost-effective treatment of hemophilia, while also eliminating the risk of infections associated with the use of plasma-derived products. Numerous companies, such as Novo Nordisk, have launched recombinant alternative products in the market, which has significantly impacted the market of plasma-derived products.

Opportunity: Increased risk of communicable disease

The increasing risk of communicable diseases such as influenza, coronavirus, and HIV is expected to drive demand for plasma fractionation products. According to the World Health Organization (WHO), the number of reported cases of communicable diseases such as HIV, malaria, and tuberculosis has been increasing consistently over the past few decades. This has necessitated the need for more efficient and effective treatments and therapies for these diseases, which is expected to drive the demand for plasma fractionation products in the coming years.

This research report categorizes the plasma fractionation market to forecast revenue and analyse trends in each of the following submarkets:

By Product

Immunoglobulins
Coagulation Factor Concentrates
Albumin
Protease Inhibitors
Other Products
By Application

Neurology
Immunology
Hematology
Critical care
Pulmonology
Hemato-oncology
Rheumatology
Other Applications
Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=93798284

North America was the largest regional market for plasma fractionation market in 2021

The global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the plasma fractionation market, followed by Europe and the Asia Pacific. The large share of North America in the global market is attributed to the innovations in manufacturing processes such as presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA, high number of registered hemophilic patients and largest number of plasma collection center. However, the market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the growth in increasing number of hemophilic patients, as well as factors such as the increasing number of organ transplantations, modified regulations and monitoring of the implementation of procedures, policies, and guidelines to promote innovation and commercialization, increasing awareness about technologically advanced products in the region, and the improving standard of living across several APAC countries.

Report Link: Plasma Fractionation Market

Table of Content:

1 INTRODUCTION (Page No. - 45)

OBJECTIVES OF THE STUDY
MARKET DEFINITION
MARKET SCOPE
CURRENCY
LIMITATIONS
RESEARCH METHODOLOGY (Page No. - 49)
RESEARCH DATA
MARKET ESTIMATION METHODOLOGY
MARKET GROWTH RATE PROJECTIONS
EXECUTIVE SUMMARY (Page No. - 60)
FIGURE 10 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)

FIGURE 11 GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)

FIGURE 12 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)

FIGURE 13 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET

PREMIUM INSIGHTS (Page No. - 63)
PLASMA FRACTIONATION MARKET OVERVIEW
NORTH AMERICA: MARKET, BY PRODUCT & COUNTRY (2021)
GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
MARKET OVERVIEW (Page No. - 66)
INTRODUCTION
MARKET DYNAMICS
IMPACT ASSESSMENT OF GLOBAL MARKET
PRICING ANALYSIS
PLASMA FRACTIONATION MARKET, BY PRODUCT (Page No. - 100)
INTRODUCTION
IMMUNOGLOBULINS
COAGULATION FACTOR CONCENTRATES
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are moulded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit MarketsandMarkets™ or follow us on Twitter, LinkedIn and Facebook.